Stay updated on ABBV-399 Safety, PK, Preliminary Efficacy in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ABBV-399 Safety, PK, Preliminary Efficacy in Solid Tumors Clinical Trial page.

Latest updates to the ABBV-399 Safety, PK, Preliminary Efficacy in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include new drug information, specifically the addition of Telisotuzumab vedotin and Erlotinib, while significant details about the ABBV-399 study, including its design and inclusion criteria, have been removed.SummaryDifference32%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 26, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 26, 2025, and version 2.14.2.SummaryDifference0.2%
- Check66 days agoChange DetectedThe webpage has updated its date references to 2025 and modified the location formatting for Seoul, Korea. Additionally, there is a duplicate entry for the Henry Ford Health System.SummaryDifference2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to ABBV-399 Safety, PK, Preliminary Efficacy in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABBV-399 Safety, PK, Preliminary Efficacy in Solid Tumors Clinical Trial page.